Idexx Laboratories CAG — Gross Profit increased by 10.5% to $667.51M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.1%, from $574.82M to $667.51M. Over 3 years (FY 2022 to FY 2025), CAG — Gross Profit shows an upward trend with a 10.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates improved pricing power or more efficient production processes, while a decrease suggests margin compression due to rising costs or competitive pricing pressure.
This metric is calculated as the total revenue of the Companion Animal Group segment minus its direct cost of revenue. I...
Comparable to segment-level gross profit margins reported by peers in the veterinary or human diagnostic equipment industries.
idxx_segment_cag_gross_profit| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $451.64M | $451.64M | $451.64M | $451.64M | $500.61M | $500.61M | $500.61M | $500.61M | $546.24M | $569.07M | $544.46M | $519.41M | $574.82M | $642.10M | $627.46M | $604.29M | $667.51M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +10.8% | +0.0% | +0.0% | +0.0% | +9.1% | +4.2% | -4.3% | -4.6% | +10.7% | +11.7% | -2.3% | -3.7% | +10.5% |
| YoY Change | — | — | — | — | +10.8% | +10.8% | +10.8% | +10.8% | +9.1% | +13.7% | +8.8% | +3.8% | +5.2% | +12.8% | +15.2% | +16.3% | +16.1% |